Quercetin and Fisetin: The Senolytic Supplements That Clear Zombie Cells

The Senescent Cell Problem#

Every time a cell divides or is exposed to DNA damage, oxidative stress, or oncogenic signals, it faces a choice: repair itself, self-destruct (apoptosis), or enter a state called cellular senescence.

Senescent cells — sometimes called "zombie cells" — stop dividing but refuse to die. In young tissue, this is protective: senescence prevents damaged cells from becoming cancerous and recruits immune cells to clear the area.

The problem is accumulation with age. The immune system becomes less efficient at clearing senescent cells. They build up in tissues across the body, secreting a toxic cocktail of inflammatory molecules, proteases, and cytokines called the SASP (Senescence-Associated Secretory Phenotype). The SASP:

• Drives chronic low-grade inflammation (inflammageing)
• Disrupts the tissue microenvironment, causing neighbouring healthy cells to become senescent
• Impairs tissue regeneration and stem cell function
• Directly contributes to the pathology of osteoarthritis, atherosclerosis, pulmonary fibrosis, cognitive decline, and sarcopenia

Eliminating senescent cells is now one of the most active areas of longevity research. The compounds that do this are called senolytics.

---

The Landmark Animal Study#

Zhu et al. (2015, Aging Cell): The first demonstration that eliminating senescent cells extends healthy lifespan. Mice genetically engineered to allow selective clearance of senescent cells showed:

• Extended median lifespan by 17–35% (depending on cohort)
• Delayed onset of cataracts, muscle weakness, and fat loss
• Improved kidney and heart function in aged mice
• Maintained physical activity and grip strength longer

This paper transformed longevity research. If removing zombie cells extended lifespan that dramatically in mice, the hunt for pharmacological senolytics — compounds that kill senescent cells selectively — became a top priority.

---

Quercetin: The First Senolytic Identified#

Quercetin is a flavonoid found in onions, capers, apples, and berries. It has a long research history as an antioxidant and anti-inflammatory, but its senolytic activity was not identified until 2015.

Zhu et al. (2015, EBioMedicine): The paper that defined the senolytic field. Quercetin (combined with dasatinib, a cancer drug) was identified as a senolytic through a bioinformatic screen and confirmed in cell culture — it selectively killed senescent cells while sparing normal cells.

Mechanism: Senescent cells survive by upregulating anti-apoptotic pathways (BCL-2 family proteins, PI3K/AKT, HSP90). Quercetin inhibits several of these survival pathways, selectively pushing senescent cells toward apoptosis. Normal cells have lower dependence on these pathways and are less affected.

Human Clinical Data#

Kirkland et al. (Mayo Clinic, 2019, EBioMedicine): The first human senolytic trial. 14 patients with idiopathic pulmonary fibrosis (a disease driven by senescent cells). Dasatinib + quercetin (D+Q) 100mg/1000mg for 3 days, repeated 3 weeks later (pulsed protocol).

Results:

• Reduced senescent cell burden (measured in skin and adipose tissue biopsies)
• Improved physical function (6-minute walk distance, chair stand time)
• Significant reduction in SASP markers (MMP-9, IL-6, IL-8, plasminogen activator inhibitor-1)

Kritchevsky et al. (2022, EBioMedicine): 20 elderly diabetic kidney disease patients. D+Q protocol showed reduced circulating SASP factors and improved physical function.

Quercetin Alone vs Dasatinib + Quercetin#

The clinical trials use dasatinib + quercetin because dasatinib (a BCR-ABL inhibitor) is more potently senolytic than quercetin alone. However, dasatinib is a chemotherapy drug with meaningful side effects — not appropriate for routine longevity supplementation.

Quercetin alone has senolytic activity, particularly against specific senescent cell types. The effect size is smaller than D+Q but clinically relevant at higher doses (500–1000mg).

---

Fisetin: The More Potent Standalone Senolytic#

Fisetin is a flavonoid found in strawberries (highest concentration), apples, onions, cucumbers, and grapes. It appeared in the senolytic literature shortly after quercetin, and subsequent research has established it as the more potent standalone senolytic.

Yousefzadeh et al. (2018, EBioMedicine): Screened 10 flavonoids for senolytic activity. Fisetin was the most potent — reducing senescent cell burden more effectively than quercetin, luteolin, and the other compounds tested.

In aged mice treated with fisetin:

• Significant reduction of senescent cells in multiple tissues
• Reduced SASP markers (IL-6, TNF-alpha, MMP-9)
• Extended median lifespan by 10% (treatment started late in life)
• Improved healthspan metrics: physical function, cognitive performance

The lifespan extension with late-life treatment is particularly notable — most longevity interventions are less effective when started late in life.

Human Fisetin Data (Emerging)#

The Mayo Clinic is running AFFIRM-LITE — the first human RCT of fisetin as a standalone senolytic in older adults. Preliminary data suggests fisetin reduces circulating SASP markers. Full results expected 2025–2026.

---

Bioavailability: The Critical Issue#

Both quercetin and fisetin have poor oral bioavailability — rapid metabolism in the gut wall and liver limits systemic exposure.

Solutions:

For quercetin:

• Take with bromelain (pineapple enzyme) — significantly improves absorption
• Quercetin phytosome (quercetin complexed with sunflower lecithin) — 20x better absorption than standard quercetin
• Take with food containing fat

For fisetin:

• Liposomal fisetin — dramatically improves bioavailability
• Fisetin with Novuseol (lipid excipient system) — enhanced absorption formula
• Take with fat-containing meal

The dose required to achieve senolytic effects in tissue is substantially higher than typical antioxidant doses. The 2018 mouse study equivalent human doses suggest 20–30mg/kg for robust senolytic activity — considerably higher than most supplement labels suggest.

Practical implication: For a 75kg person, a senolytic dose of fisetin is 1,500–2,250mg. Most supplements contain 100mg. High-dose approaches are used for the pulsed protocols.

---

The Pulsed Protocol#

This is the critical difference between senolytics and most supplements: do not take them daily.

Senolytics are most effective when used intermittently — a burst of activity that eliminates a cohort of senescent cells, followed by a rest period during which normal cells recover and new senescent cells accumulate before the next clearing.

Daily low-dose supplementation may actually be counterproductive — chronic exposure allows senescent cells to develop resistance to the apoptotic signal.

Protocol Options#

Conservative pulsed protocol:

• Fisetin 500–1000mg/day for 2 consecutive days
• Repeat monthly or quarterly
• Take with fat-containing meals for best absorption

Research-informed protocol (higher dose):

• Fisetin 1,000–2,000mg/day for 2 days
• Quercetin 500–1,000mg/day alongside (for complementary mechanisms)
• Once per month or every 6 weeks
• Take with food; divide into 2 doses (morning and midday)

Simplest approach:

• Fisetin 500mg twice daily, 2 days per month
• No cycling complexity; straightforward to maintain

---

Stacking With Other Longevity Interventions#

Navitoclax concern: Navitoclax is a more potent pharmaceutical senolytic (BCL-2/BCL-xL inhibitor) used in cancer treatment with significant toxicity. Do not confuse research on pharmaceutical senolytics with the flavonoid compounds discussed here.

Synergistic approaches:

• Fasting before senolytic pulse: A 24-hour fast before the 2-day fisetin protocol may increase senolytic effectiveness — fasting itself activates some apoptotic pathways in senescent cells, and the fisetin then pushes them over the threshold
• Exercise after pulse: Exercise-induced clearance of cellular debris may complement the senolytic clearing
• NAD+ precursors: NMN/NR alongside senolytics — NAD+ supports the repair of nearby healthy cells

---

Safety#

Quercetin and fisetin at the doses described have excellent safety profiles across multiple clinical trials. Both are naturally occurring flavonoids with long dietary histories.

Drug interactions:

• Quercetin inhibits CYP3A4 — may increase levels of drugs metabolised by this enzyme (statins, some blood pressure medications, immunosuppressants). Discuss with your physician.
• Fisetin has similar interactions at high doses

Contraindications:

• Pregnancy and breastfeeding — insufficient safety data
• Prior to surgery — mild antiplatelet effects; stop 1 week before planned procedures
• With medications metabolised by CYP3A4 (check with your pharmacist)

---

Bottom Line#

Senolytics represent one of the most mechanistically compelling interventions in longevity medicine. The animal data is extraordinary; the human data is emerging and early but directionally consistent.

Fisetin is the best standalone senolytic available OTC — more potent than quercetin per milligram, with good safety data and growing human evidence. Used in a monthly 2-day pulsed protocol at 500–2000mg/day, it is one of the most intriguing longevity interventions currently accessible without a prescription.

The field will clarify over the next 3–5 years as AFFIRM-LITE and other human trials report. For now, the risk-benefit profile — safe, inexpensive compounds with mechanistically grounded and animal-validated activity — makes the pulsed fisetin protocol a reasonable inclusion in an evidence-informed longevity stack.